Nasdaq:ARTL
ARTELO BIOSCIENCES, INC.
A clinical-stage biotech firm advancing novel cancer therapies with a strong focus on R&D and strategic capital raising.
Key Metrics
Investment Thesis
Bull Case
Investors might consider ARTL if they believe in the transformative potential of its proprietary cancer platform and expect a successful partnership deal or licensing agreement that could provide non-dilutive funding. The company's small market cap offers significant upside potential if one of its drug candidates receives FDA approval, potentially re-rating the stock significantly upon commercialization. Strategic alliances with larger pharmaceutical companies could provide the necessary capital injection and distribution channels to launch therapies.
Bear Case
The stock carries extreme risk due to a negative shareholders' equity of $1.3M and a retained earnings deficit of $63.0M, indicating that current assets cannot cover total liabilities without external support. With no revenue stream and operating losses widening year-over-year from $9.3M in 2023 to $12.9M in 2025, the company is burning through its limited cash reserves at a rate that threatens solvency. The lack of profitability and reliance on dilutive equity issuances suggests that shareholders may face continued erosion of ownership percentage before any return on investment is realized.
About ARTELO BIOSCIENCES, INC.
ARTELO BIOSCIENCES, INC. (ARTL) is a clinical-stage biotechnology company focused on developing innovative therapies to treat cancer and other serious diseases. The company operates primarily in the United States, leveraging its proprietary platforms to advance multiple drug candidates through preclinical and clinical development stages. With zero revenue reported in the latest period, ARTL relies on strategic financing and cash reserves to fund its extensive research and development efforts.
Analysis
Management Discussion
In the most recent fiscal year, ARTELO reported a net loss of $12.9M, driven by $5.4M in research and development expenses and $6.0M in general and administrative costs. While cash flow from operations was negative at $8.5M, the company successfully raised $6.9M through financing activities, including $6.2M from share issuances, to extend its runway. The company's cash balance remained stable at $600,000, but the continued burn rate without any product approvals highlights the precarious financial position typical of late-stage or clinical-stage biotech firms.
Industry Overview
The biotechnology industry is characterized by high failure rates in drug development, where only a small fraction of candidates successfully reach market approval. Companies like ARTELO operate in a capital-intensive environment requiring substantial funding to navigate the lengthy and expensive clinical trial process. Market dynamics are heavily influenced by regulatory decisions from bodies like the FDA, making success unpredictable and volatile for investors.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $10.3M | $9.9M | $10.1M | $11.4M |
| Operating Income | $-10.3M | $-9.9M | $-10.1M | $-11.4M |
| R&D | $4.3M | $5.7M | $6.0M | $5.4M |
| G&A | $6.0M | $4.2M | $4.1M | $6.0M |
| Stock-Based Comp | $2.5M | $1.0M | $818.0K | $1.1M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5.0K | $0 | — | $194.0K |
| Pre-Tax Income | $-10.3M | $-9.9M | $-10.1M | $-11.4M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-10.3M | $-9.9M | $-10.1M | $-11.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $10.1M | $-9.3M | $-9.8M | $-12.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $10.1M | $-9.3M | $-9.8M | $-12.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $18.3M | $11.0M | $2.6M | $695.0K |
| Cash & Equivalents | $6.9M | — | — | $600.0K |
| Marketable Securities | $9.2M | $7.6M | $0 | — |
| Prepaid Expenses | — | $554.0K | $219.0K | $95.0K |
| Other Current Assets | $2.3M | $2.8M | $2.3M | $0 |
| Long-Term Assets | $2.1M | $2.1M | $2.1M | $2.1M |
| Intangibles | $2.0M | $2.0M | $2.0M | $2.0M |
| Operating Leases | $60.0K | $21.0K | $99.0K | $64.0K |
| LT Securities | $9.2M | $7.6M | $0 | — |
| Other LT Assets | $-9.1M | $-7.6M | $3.0K | $3.0K |
| Total Assets | $20.4M | $13.0M | $4.7M | $2.8M |
| Current Liabilities | $998.0K | $1.3M | $1.8M | $4.0M |
| Current Leases | $40.0K | $23.0K | $35.0K | $40.0K |
| Other Current Liab | $958.0K | $1.3M | $1.7M | $4.0M |
| Long-Term Liabilities | $23.0K | $0 | $69.0K | $29.0K |
| LT Operating Leases | $23.0K | $0 | $69.0K | $29.0K |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.0M | $1.3M | $1.8M | $4.1M |
| Shareholders' Equity | $19.4M | $11.8M | $2.9M | $-1.3M |
| Paid-In Capital | $50.7M | $52.3M | $53.2M | $62.0M |
| Retained Earnings | $-31.0M | $-40.3M | $-50.1M | $-63.0M |
| AOCI | $-254.0K | $-203.0K | $-202.0K | $-272.0K |
| Total L&E | $20.4M | $13.0M | $4.7M | $2.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $10.1M | $-9.3M | $-9.8M | $-12.9M |
| Non-Cash Adjustments | $-18.3M | $419.0K | $1.5M | $2.9M |
| Working Capital Changes | $175.0K | $663.0K | $-7.0K | $1.5M |
| Cash from Operations | $-8.0M | $-8.2M | $-8.3M | $-8.5M |
| Cash from Investing | $3.0M | $3.5M | $7.8M | $-62.0K |
| Cash from Financing | $0 | $567.0K | $112.0K | $6.9M |
| FX Effect | $-224.0K | $60.0K | $-8.0K | $-23.0K |
| Net Change in Cash | $-5.3M | $-4.1M | $-477.0K | $-1.7M |
| Beginning Cash | $12.2M | $6.9M | $2.8M | $2.3M |
| Ending Cash | $6.9M | $2.8M | $2.3M | $600.0K |
Frequently Asked Questions
How does ARTELO BIOSCIENCES, INC. make money?
The company's operations are driven by two primary segments: drug discovery and development, which includes the identification and optimization of new therapeutic candidates, and preclinical and clinical services, encompassing the execution of trials to evaluate safety and efficacy. Additionally, the firm manages intellectual property licensing and potential strategic partnerships as a secondary revenue stream contingent on future deal closures.
What are the main risks for ARTL?
The primary risk is the complete absence of commercial revenue, making the company entirely dependent on successful fundraising to cover substantial operating losses. There is significant uncertainty regarding the success of clinical trials, as a single failure can wipe out years of development investment and deplete cash reserves rapidly. Regulatory hurdles in bringing new drugs to market pose additional challenges, including potential delays or rejections by the FDA that could halt development timelines.
What is ARTL's competitive advantage?
ARTL possesses a proprietary platform technology that targets critical pathways in cancer cell biology, offering a differentiated approach compared to traditional small molecule inhibitors. The company benefits from an experienced management team with deep expertise in oncology drug development and regulatory navigation. Its lean organizational structure allows for agile decision-making and efficient allocation of limited resources toward high-potential asset selection.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.